Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias

Brain

Volumn 134, Issue 4, 2011, Pages 979-986

  Ahmed, Imtiaz ^a   Bose, Subrata K ^a   Pavese, Nicola ^a,c   Ramlackhansingh, Anil ^a   Turkheimer, Federico ^a   Hotton, Gary ^a   Hammers, Alexander ^a,b   Brooks, David J ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b HÔPITAL NEUROLOGIQUE   (France)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

dyskinesias; glutamate; levodopa; Parkinson; PET

Indexed keywords

CABERGOLINE; ION CHANNEL; LEVODOPA; N METHYL 3(THYOMETHYLPHENYL)CYANAMIDE C 11; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PERGOLIDE; PRAMIPEXOLE; RADIOPHARMACEUTICAL AGENT; RASAGILINE; ROPINIROLE; ROTIGOTINE; UNCLASSIFIED DRUG;

AGED; ARTICLE; BASAL GANGLION; CAUDATE NUCLEUS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DYSKINESIA; FEMALE; GLUTAMATE TRANSMISSION; HUMAN; LEVODOPA INDUCED DYSKINESIA; MALE; MOTOR CORTEX; NEUROTRANSMISSION; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIMARY MOTOR CORTEX; PRIORITY JOURNAL; PUTAMEN; UNIFIED PARKINSON DISEASE RATING SCALE;

EID: 79953647380     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awr028     Document Type: Article

References (46)

1. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001; 16: 448-58. (Pubitemid 36041148)
2. Bamford NS, Robinson S, Palmiter RD, Joyce JA, Moore C, Meshul CK. Dopamine modulates release from corticostriatal terminals. J Neurosci 2004; 24: 9541-52. (Pubitemid 39441508)
3. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561-71.
4. Bibbiani F, Oh JD, Kielaite A, Collins MA, Smith C, Chase TN. Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD. Exp Neurol 2005; 196: 422-29. (Pubitemid 41607831)
5. Biegon A, Gibbs A, Alvarado M, Ono M, Taylor S. In vitro and in vivo characterization of [3H]CNS-5161-a use-dependent ligand for the N-methyl-D-aspartate receptor in rat brain. Synapse 2007; 61: 577-86. (Pubitemid 46934004)
6. Braz CA, Borges V, Ferraz HB. Effect of riluzole on dyskinesia and duration of the on state in Parkinson disease patients: a doubleblind, placebo-controlled pilot study. Clin Neuropharmacol 2004; 27: 25-9. (Pubitemid 38280384)
7. Brix G, Zaers J, Adam LE, Bellemann ME, Ostertag H, Trojan H, et al. Performance evaluation of a whole-body PET scanner using the NEMA protocol. National Electrical Manufacturers Association. J Nucleic Med 1997; 38: 1614-23. (Pubitemid 27443965)
8. Calabresi P, Giacomini P, Centonze D, Bernardi G. Levodopa induced dyskinesia: a pathological form of striatal synaptic plasticity? Ann Neurol 2000; 47: 60-8.
9. Calon F, Morissette M, Ghribi O, Goulet M, Grondin R, Blanchet PJ, et al. Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment. Progr Neuro-Psychopharmacol Biol Psych 2002; 26: 127-38. (Pubitemid 34045159)
10. Calon F, Rajput AH, Hornykiewicz O, Bedard PJ, Di Paolo T. Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiol Dis 2003; 14: 404-16. (Pubitemid 37543519)
11. Carlsson T, Carta M, Winkler C, Bjö rklund A, Kirik D. Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease. J Neurosci 2007; 27: 8011-22. (Pubitemid 47173327)
12. Carta M, Carlsson T, Muñoz A, Kirik D, Bjö rklund A. Role of serotonin neurons in the induction of levodopa- and graft-induced dyskinesias in Parkinson's disease. Mov Disord 2010; 25(Suppl. 1): S174-9.
13. Chase TN, Oh JD. Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci 2000; 23(Suppl. 10): S86-91.
14. Cunningham V, Jones T. Spectral analysis of dynamic PET studies. J Cereb Blood Flow Metab 1993; 13: 15-23. (Pubitemid 23016599)
15. Dagher A, Gunn R, Lockwood G, Cunningham V, Grasby P, Brooks DJ. Measuring neurotransmitter release with PET: methodological issues. In: Carson RE, Daube-Witherspoon ME, Herscovitch P, editors. Quantitative functional brain imaging with positron emission tomography. San Diego: Academic Press; 1998. p. 449-54.
16. De la Fuente-Fernández R, Sossi V, Huang Z, Furtado S, Lu JQ, Calne DB, et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 2004; 127: 2747-54. (Pubitemid 39627382)
17. Del Dotto P, Pavese N, Gambaccini G, Bernardini S, Metman LV, Chase TN, et al. Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study. Mov Disord 2001; 16: 515-20. (Pubitemid 36041158)
18. Engber TM, Susel Z, Kuo S, Gerfen CR, Chase TN. Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats. Brain Res 1991; 552: 113-8.
19. Fahn S, Elton RL. Members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. Recent developments in Parkinson's disease, II. Florham Park: MacMillan Headcare Information; 1987. p. 153-64.
20. Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
21. Foster AC, Wong EH. The novel anticonvulsant MK-801 binds to the activated state of the N-methyl-D-aspartate receptor in rat brain. Br J Pharmacol 1987; 91: 403-9. (Pubitemid 17083987)
22. Gulledge AT, Jaffe DB. Dopamine decreases the excitability of layer V pyramidal cells in the rat prefrontal cortex. J Neurosci 1998; 18: 9139-51. (Pubitemid 28491775)
23. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
24. Hammers A, Allom R, Koepp MJ, Free SL, Myers R, Lemieux L, et al. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp 2003; 19: 224-47. (Pubitemid 36959351)
25. Heckemann RA, Hajnal JV, Aljabar P, Rueckert D, Hammers A. Automatic anatomical brain MRI segmentation combining label propagation and decision fusion. Neuroimage 2006; 33: 115-26. (Pubitemid 44404167)
26. Henry B, Duty S, Fox SH, Crossman AR, Brotchie JM. Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease. Exp Neurol 2003; 183: 458-68. (Pubitemid 37205087)
27. Kotecha SA, Oak JN, Jackson MF, Perez Y, Orser BA, Van Tol HH, et al. A D2 class dopamine receptor transactivates a receptor tyrosine kinase to inhibit NMDA receptor transmission. Neuron 2002; 35: 1111-22. (Pubitemid 35279538)
28. Merello M, Nouzeilles MI, Cammarota A, Leiguarda R. Effect of mem-antine (NMDA antagonist) on Parkinson's disease: a doubleblind crossover randomized study. Clin Neuropharmacol 1999; 22: 273-6. (Pubitemid 29506396)
29. Nash JE, Brotchie JM. Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat. Mov Disord 2002; 17: 455-66. (Pubitemid 36040956)
30. Oh JD, Russell DS, Vaughan CL, Chase TN, Russell D. Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopa-minergic denervation and L-DOPA administration. Brain Res 1998; 813: 150-9. (Pubitemid 29012528)
31. Parkinson Study Group. Evaluation of dyskinesias in a pilot, randomized, placebo-controlled trial of remacemide in advanced Parkinson disease. Arch Neurol 2001; 58: 1660-8.
32. Pavese N, Evans AH, Tai YF, Hotton G, Brooks DJ, Lees AJ, et al. Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study. Neurology 2006; 67: 1612-7. (Pubitemid 44747932)
33. Robelet S, Melon C, Guillet B, Salin P, Kerkerian-Le Goff L. Chronic L-DOPA treatment increases extracellular glutamate levels and GLT1 expression in the basal ganglia in a rat model of Parkinson's disease. Eur J Neurosci 2004; 20: 1255-66. (Pubitemid 39233578)
34. Samadi P, Rajput A, Calon F, Gré goire L, Hornykiewicz O, Rajput AH, et al. Metabotropic glutamate receptor II in the brains of Parkinsonian patients. J Neuropathol Exp Neurol 2009; 68: 374-82.
35. Studholme C, Hill DL, Hawkes DJ. Automated three-dimensional registration of magnetic resonance and positron emission tomography brain images by multiresolution optimization of voxel similarity measures. Med Phys 1997; 24: 25-35. (Pubitemid 27051930)
36. Surmeier DJ, Ding J, Day M, Wang Z, Shen W. D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci 2007; 30: 228-35. (Pubitemid 46654239)
37. Svenningsson P, Arts J, Gunne L, Andren PE. Acute and repeated treatment with L-DOPA increase c-jun expression in the 6-hydroxydopamine-lesioned forebrain of rats and common marmosets. Brain Res 2002; 955: 8-15. (Pubitemid 35284830)
38. Tedroff J, Pedersen M, Aquilonius SM, Hartvig P, Jacobsson G, Langstrom B. Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET. Neurology 1996; 46: 1430-6.
39. Tomiyama M, Kimura T, Maeda T, Tanaka H, Kannari K, Baba M. Upregulation of striatal adenosine A2A receptor mRNA in 6-hydroxydopamine-lesioned rats intermittently treated with L-DOPA. Synapse 2004; 52: 218-22. (Pubitemid 38581671)
40. Turkheimer F, Moresco RM, Lucignani G, Sokoloff L, Fazio F, Schmidt K. The use of spectral analysis to determine regional cerebral glucose utilization with positron emission tomography and [18F]fluorodeoxyglucose: theory, implementation, and optimization procedures. J Cereb Blood Flow Metab 1994; 14: 406-22.
41. Turkheimer FE, Brett M, Visvikis D, Cunningham VJ. Multiresolution analysis of emission tomography images in the wavelet domain. J Cereb Blood Flow Metab 1999; 19: 1189-208. (Pubitemid 30176447)
42. Turkheimer FE, Edison P, Pavese N, Roncaroli F, Anderson AN, Hammers A, et al. Reference and target region modeling of [11C]-(R)-PK11195 brain studies. J Nucl Med 2007; 48: 158-67. (Pubitemid 47555390)
43. Turkheimer FE, Hinz R, Cunningham VJ. On the undecidability among kinetic models: from model selection to model averaging. J Cereb Blood Flow Metab 2003; 23: 490-8. (Pubitemid 36403031)
44. Verhagen-Metman L, Del Dotto P, Natté R, van den Munckhof P, Chase TN. Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease. Neurology 1998a; 51: 203-6. (Pubitemid 28345384)
45. Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998b; 50: 1323-6. (Pubitemid 28240346)
46. Zeng BY, Pearce RK, MacKenzie GM, Jenner P. Alterations in preproen-kephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA. Eur J Neur 2000; 12: 1096-104. (Pubitemid 30168788)